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Although development leads unidirectionally toward more restricted cell fates, recent work in
cellular reprogramming has proven that one cellular identity can strikingly convert into another,
promising countless applications in biomedical research and paving the way for modeling diseases
with patient-derived stem cells. To date, there has been little discussion of which disease models
are likely to be most informative. Here, we review evidence demonstrating that, because environ-
mental influences and epigenetic signatures are largely erased during reprogramming, patient-
specific models of diseases with strong genetic bases and high penetrance are likely to prove
most informative in the near term. We also discuss the implications of the new reprogramming
paradigm in biomedicine and outline how reprogramming of cell identities is enhancing our under-
standing of cell differentiation and prospects for cellular therapies and in vivo regeneration.As a zygote cleaves and then develops into a complex organism,
cells transition inexorably from one identity to another. Gene
expression from a single genome naturally evolves and adapts
via a carefully choreographed and directed set of inductive and
selective events until lineages become segregated and tissue
fates are fixed. This ability of a multicellular organism to create
diverse cell types from a single stable genome provides versa-
tility of function, permitting an organism to adapt and thrive in
more varied environments than their single-cell predecessors.
Although a few complex organisms, such as salamanders,
regenerate large portions of their bodies by dedifferentiating
their tissues,mostmulticellular organisms demonstrate very little
reversibility of cellular identity after completing embryogenesis.
Adult mammals are unable to regenerate anatomically correct
organ systems after significant damage or loss, demonstrating
that cellular identities in the unaffected tissues are largely stable.
Even in the few mammalian organs with high rates of cell turn-
over, such as the skin, blood system, and gut, the range of
possible cell fates is rigidly restricted to those cellular identities
comprising the specific tissue.
Evolution has invested heavily in maintaining and restricting
cellular identities in mammals. Once a mammalian cell has pro-
gressed through its natural developmental and regenerative
transitions, its final, specialized state is sustained by a loss of
self-renewal and inevitable senescence. Mutations in the genetic
mechanisms of cellular identity, stability, and senescence
predispose cells to the development of malignancy. For
example, when granulocyte macrophage precursors acquire
self-renewal, these otherwise normal progenitors are trans-1110 Cell 148, March 16, 2012 ª2012 Elsevier Inc.formed into leukemic stem cells (Krivtsov et al., 2006). Pathologic
conditions that encourage fluidity of cellular identity can similarly
predispose individuals to cancer. Patients with gastresophageal
reflux are a classic example of this phenomenon, in which expo-
sure to stomach acid causes affected regions of the esophagus
to transform into stomach-like tissue. This tissue metaplasia,
while protecting the integrity of the esophagus, also predisposes
patients to adenocarcinoma (Lagergren et al., 1999).
The in vivo mechanisms by which a differentiated cell transi-
tions to another cell type (metaplasia) or to a more undifferenti-
ated phenotype (dysplasia) are under investigation. Current
research suggests that these in vivo alterations of cellular identi-
ties are brought about by changes in the epigenome and gene
expression of the affected cells, which in turn provide fertile
ground for the appearance of mutations that promote malignant
transformation (Kang et al., 2003; Nardone et al., 2007; Herfs
et al., 2009).
Manipulating Cellular Identity In Vitro
The orderly progression of cell differentiation during develop-
ment has been well described by in vivo studies, but some ques-
tions can be addressed more directly in the highly controlled
environment of in vitro tissue culture. Human embryonic stem
(ES) cells, derived from the inner cell masses of human blasto-
cysts, were first successfully derived less than 15 years ago by
the Thomson group from the University of Wisconsin (Thomson
et al., 1998). Pluripotent cells are unique in that they can be
grown indefinitely while retaining the ability to differentiate into
all three embryonic tissue lineages. Human ES cell derivation
Figure 1. Fluidity of Cellular Identity In Vivo and In Vitro
Cellular identity is the sum of a cell’s epigenetic landscape. It can become
altered through numerous in vivo processes, including development, meta-
plasia, and dysplasia. It can also bemanipulated by experimenters in protocols
such as directed differentiation, transdifferentiation, and reprogramming.has inspired biomedical scientists to use stem cells to address
questions of human developmental biology, to study disease
processes in vitro, and even to attempt to replace ailing tissues
in human patients. All of these hopes have been pinned on the
ability of scientists to engineer specific cellular identities.
This is an ambitious goal. Murine ES cells have been in wide-
spread use for three decades, and yet attempts to generate
functional mouse blood cells, pancreatic cells, and highly
specialized neurons have so far proven only partly successful.
Nonetheless, biologists remain confident that ES cells can be
differentiated to specific cell types if culture conditions can be
identified that precisely mimic the organizational and signaling
events of the developing embryo. This approach necessitates
an in-depth understanding of the cellular identity changes that
take place in normal development and requires direct translation
of basic developmental biology into painstakingly developed
protocols for directed differentiation.
During in vitro differentiation, stem cells are induced to form
aggregates with predictable structures (i.e., embryoid bodies)
that echo embryonic organization, and growth factors have
been identified that coax pluripotent cells toward one lineage or
another. These approaches attempt to recapitulate the epigenetic
changes that occur during embryogenesis, with the aim of
creating tissue types analogous to those generatedduring embry-
onic development. In the years since the first human ES cell deri-
vation, scientistshavecrafteddifferentiationprotocols togenerate
many cell types, including motor neurons, retinal pigment epithe-
lium, and hematopoietic precursors from human ES cells (Wich-
terle et al., 2002; Klimanskaya et al., 2004; Ng et al., 2005). These
protocols exemplify the reigning paradigm that in vitro manipula-
tions of cellular identity should follow the course of the natural,
unidirectional changes that occur during development.
This paradigm was overthrown in 2006, when Takahashi and
Yamanaka published the distinctly unnatural conversion ofmurine fibroblasts into induced pluripotent stem (iPS) cells
(Takahashi and Yamanaka, 2006). Their approach was blatantly
not based on mimicking developmental events, and the cellular
fate change that they engineered went backward—the implau-
sible reversion of a differentiated, specialized somatic cell to
a pluripotent embryonic progenitor.
Although conversion of differentiated cells to an embryonic
state had previously been accomplished by somatic cell nuclear
transfer, that process was and remains to this day inefficient,
cumbersome, and poorly understood (Rideout et al., 2001).
The Yamanaka reprogramming approach, on the other hand,
used a few defined factors to convert a cell to a radically different
identity. This landmark study compelled a bold paradigm shift
and introduced the engineering of cell identity as a powerful
new strategy for biomedical research and regenerative
medicine.
The pluripotency of murine iPS cells has been established in
many ways, including gene expression and epigenome profiling,
chimera formation, and tetraploid embryo complementation
(Okita et al., 2007; Zhao et al., 2009). Soon after the publication
of reprogramming in murine cells, multiple labs confirmed that
ectopic expression of defined factors could also generate iPS
cells from human tissues (Yu et al., 2007; Takahashi et al.,
2007; Park et al., 2008b). Both gene expression and epigenetic
studies revealed that iPS cells are strikingly more similar to ES
cells than they are to their starting cell type (Hawkins et al.,
2010; Doi et al., 2009; Kim et al., 2010; Polo et al., 2010), showing
that transduction of four transcription factors (i.e., Oct4, Sox2,
Klf4, and c-Myc) indeed alters mammalian cellular identities in
the direction opposite to that of development. Although multiple
groups had induced modest cell fate changes between meso-
dermal or hematopoietic lineages by manipulating transcription
factors (Davis et al., 1987; McNagny and Graf, 2002; Cobaleda
et al., 2007), engineering cell fate changes as dramatic as rever-
sion of differentiated cells to pluripotency was not envisioned as
plausible before Yamanaka’s work.
The original publication of iPS cell reprogramming has inspired
researchers to attempt manipulations of cellular identity in new
and unexpected directions. Ectopic transcription factor expres-
sion is now being investigated as a tool to perform direct conver-
sion, or ‘‘transdifferentiation,’’ of one differentiated cell type to
another, including neurons and cardiomyocytes from fibroblasts
and b cells from exocrine cells (Zhou et al., 2008; Vierbuchen
et al., 2010; Ieda et al., 2010; Efe et al., 2011). Protocols continue
to be published for the generation of differentiated cell types
from pluripotent stem cells, for more effective generation of
stem cells from somatic cells, and for the conversion of one
differentiated cell type to another.
This diversity of goals represents a radical change in thinking
about the categories of identity changes that can be effected
in vitro (Figure 1): adult mammalian cellular identity can be
manipulated not only in the direction of stem cell differentiation
(a correlate of normal development), but also dedifferentiation
(a correlate of dysplasia) and transdifferentiation (a correlate of
metaplasia). The recent appreciation for the plasticity of cellular
identity has made this area one of the most exciting topics in
modern stem cell biology. Takahashi and Yamanaka’s seminal
publication has compelled a new and creative open-mindednessCell 148, March 16, 2012 ª2012 Elsevier Inc. 1111
about cellular identity and has paved the way for the develop-
ment of iPS cell-based disease models, drug screens, and
cellular therapies. The prospects for cellular therapies are still
on the horizon, but use of reprogramming technology for disease
modeling and drug testing has already begun. This Perspective
provides a discussion on which disease categories are likely to
benefit in the near future from reprogramming-based models
and how these models can be used to study gene-environment
interactions.
Reprogramming-Based Disease Models Provide a New
Platform for Disease Research
Research into human disease can be performed on platforms as
diverse as epidemiology, human genetics, animal modeling, and
in vitro cell culture. Each of these approaches provides different
kinds of information about the disease under investigation, and
each has its own limitations. It is not often that a new platform
for studying disease arises, but in the last few years, the advent
of patient-specific pluripotent stem cells has inspired
researchers to contemplate modeling diseases in a powerful
new way.
By differentiating patient-specific iPS lines into the cell type
responsible for a specific disorder, scientists hope to gain
many new research tools. For disorders in which etiology is
unclear, such as type I diabetes, it is theorized that patient-
specific iPS cell models may confirm current theories or inspire
new hypotheses about the origins and progression of the
disease (Maehr et al., 2009). For diseases in which human-
specific cardiac or renal toxicity is a limiting factor in treatment,
stem cell-derivedmodels of heart or renal tissuesmay be used to
experimentally measure and reduce drug associated toxicity.
Finally, for any disorder whose iPS cell-derived target cells
show a measurable disease-specific phenotype, reprogram-
ming-based models can be used as screening tools for develop-
ment of new drugs that reverse the cellular pathology in vitro and
might therefore carry a greater probability of reversing disease
pathology when given to patients.
Because of the inherent pluripotency of the starting cells, their
potential applications for cell-autonomous disorders touch
virtually every organ system. Researchers studying disorders
of hematological, neurological, cardiovascular, metabolic, endo-
crine, andmuscular cell types have already begun the process of
creating disease models by reprogramming disease-specific
primary cell samples from patients with cystic fibrosis, Hunting-
ton’s disease, Parkinson’s disease, sickle cell anemia, dyskera-
tosis congenita, familial amyotrophic lateral sclerosis, and a
growing compendium of other conditions recently reviewed by
Grskovic et al. (2011) (Park et al., 2008b; Dimos et al., 2008;
Mali et al., 2008; Somers et al., 2010; Ghodsizadeh et al.,
2010; Agarwal et al., 2010). These inexhaustible sources of
patient-specific cells are then differentiated toward the lineage
affected by the disorder, be it neural, hematopoietic, cardiac,
or hepatic. Once the cell type that is responsible for the disease
has been generated, researchers attempt to identify a disease-
associated phenotype that manifests characteristics relevant
to the disorder. Such cells represent a new research platform
for studying bothmechanisms and genotype-phenotype interac-
tions of the disease.1112 Cell 148, March 16, 2012 ª2012 Elsevier Inc.For example, congenital long-QT syndrome has been difficult
to study in vitro because of the inaccessibility of human cardio-
myocytes carrying the causal genetic mutations (Behr et al.,
2008). In a recent study by Moretti et al., iPS cells were derived
from individuals with monogenic congenital long-QT syndrome
type I, differentiated to cardiac lineages, and assayed for charac-
teristic electrophysiological traits (Moretti et al., 2010). The
patient-derived cardiomyocytes showed longer-lasting action
potentials than the healthy controls, as well as an altered protein
localization pattern. These findings allowed the authors to
identify a dominant-negative mechanism of disease. A paper
released shortly afterward described similar studies on another
variant of congenital long-QT syndrome, caused by a mutation
in a different gene (Itzhaki et al., 2011). This study identified
additional disease-associated electrophysiological phenotypes
in the patients’ cells, and the authors were able to conduct
a limited drug screen to investigate the potency of chemical
compounds to ameliorate the disease traits. The existence of
these two models will allow for direct comparison of cellular
phenotypes between different genotypes of the same disease
and will hopefully lead to improved, personalized therapeutic
options for patients (Figure 2).
Because of these many and varied benefits, reprogramming-
based diseasemodels are being rapidly adopted by translational
scientists. Dozens have already been published and are the
subject of recent review articles (Grskovic et al., 2011; Tiscornia
et al., 2011; Unternaehrer and Daley, 2011). However, the field of
iPS cell-based disease modeling is still in its infancy, and many
challenges remain. Most disease systems still face significant
hurdles that need to be overcome before iPS technology can
deliver on its promise. The following are specific challenges
that each disease field must address.
Directed Differentiation and Cell Culture Protocols
For many years, work has been underway to convert pluripotent
cells into target cell types. Some highly specialized cell types like
motor neurons and cardiomyocytes have been created with
great fidelity using protocols that mimic pathways defined
through studies of embryo development. In contrast, only close
facsimiles of other much sought-after cell types, like b cells, have
been created using independent protocols in different laborato-
ries, with phenotypes that differ from actual human target cells
(Kroon et al., 2008; Zhang et al., 2009). Some cell types, such
as definitive hematopoietic stem cells (HSCs), have never been
successfully derived from pluripotent stem cells purely in vitro.
In cases like HSCs, the difficulty rests in large part on the lack
of suitable culture conditions to maintain and expand these
evanescent cells. Where cell culture conditions remain poorly
defined, directed differentiation protocols represent a critical
rate-limiting step in iPS cell research.
Definition of ‘‘Target’’ Cell
Cellular identity is a complex phenotype with many components.
For research to proceed on a given iPS cell-derived cell type,
the field must first agree that the in vitro product is comparable
to its in vivo correlate. This measure of similarity must occur on
multiple levels and include analysis of gene expression, chro-
matin state, and functional assays. Transcriptional activity and
methylomes can be evaluated by similar methodologies in all
cell types, but appropriate markers of cell identity as well as
Figure 2. The Promise of Reprogramming-Based Disease Models
iPS cell-based models promote research into disease mechanisms, create a framework for screening possible drug compounds, and provide the opportunity to
compare different disease genotypes.choice and validation of cell type-specific functional assaysmust
be specifically identified for all target cell types.
Identification of Appropriate Disease-Specific Cellular
Phenotypes
In some cases, target cell types derived from disease-specific
iPS cells show clear and predictable phenotypes, such as the
electrophysiological abnormalities in the cardiomyocytes
described above. For other diseases, the appropriate assay for
disease phenotype is unclear or may not show a significant
difference between disease and nondisease lines. For example,
recent papers have derived iPS lines from patients with idio-
pathic Parkinson’s disease (PD) and normal controls (Soldner
et al., 2009; Hargus et al., 2010). The researchers planned to
investigate whether PD-iPS cell lines would form dopaminergic
neurons at lower frequencies than WT-iPS cells during directed
differentiation, as well as how dopaminergic neuron grafts would
function in transplantation assays into various animal models of
PD. In practice, none of these endpoints showed any difference
between the disease and the control-derived iPS cells. The
researchers eventually identified only a single outcome measurein the rodent model that showed a significant difference between
the two cell types out of three behavioral tests that were admin-
istered after PD was induced.
This case underscores the difficulty that befalls the investi-
gator when deciding whether a true phenotypic difference
indeed reflects the underlying disease pathophysiology. In
another recent paper investigating progeria, the search for a
stress-related phenotype in iPS-derived cells led to creative
assays such as submersing cells in oil for 5 hr or exposing
them to electrical stimulation for 3 days (Zhang et al., 2011a).
As the search for new disease models expands, cases like this
should serve as an instructive reminder that investigators are
responsible for demonstrating that their ‘‘disease-associated
phenotypes’’ are biologically relevant to the disease at hand.
Identification of Diseases Amenable to iPS Cell-Based
Modeling
To date, there has been little discussion about which disorders
are likely to be best informed by iPS cell models. The idiopathic
PD example is a cautionary tale that disease modeling with iPS
cells will be more informative for some types of disease thanCell 148, March 16, 2012 ª2012 Elsevier Inc. 1113
for others. Reprogramming may still be too new of a technical
advance to reliably predict which diseases can be effectively
modeled and which will not. However, in the long term, it will
behoove the field to establish a methodology for analyzing
successful and unsuccessful modeling attempts to identify the
factors that predict success. Considerations are discussed
below for determining whether a particular disease research field
is likely to be well served by reprogramming-based models.
Identification of Disorders Best Suited to ES Cell-Based
Disease Modeling
Disease-specific ES lines from preimplantation genetic diag-
nosis are likely to be better suited for research on certain ques-
tions than iPS cell lines. One example of this is fragile X
syndrome (FX), in which the FMR1 gene is inappropriately
silenced during development. Because of a failure to reactivate
the mutant locus during reprogramming (Urbach et al., 2010),
FX-iPS cells do not express the FMR1 gene. Thus, though FX-
iPS cells may give rise to FMR-deficient neurons (Sheridan
et al., 2011), they do not allow studies of the mechanisms by
which pathological gene silencing occurs during development.
Reprogramming Imperfectly Resets the Epigenome
to an ES Cell-Like State
Several studies have compared the epigenetic status of iPS cells
to that of ES cells and the starting somatic cell type. The global
methylation profiles of iPS cells are much closer to ES cells
than they are to their tissue of origin (Doi et al., 2009; Lister
et al., 2011), reflecting the phenotypic and functional similarities
shared by the pluripotent cells and confirming that the reprog-
ramming process resets the vast majority of the iPS cell epige-
nome to an ES-like state. However, the epigenomes of the two
pluripotent cell types are not identical.
Specific classes of epigenetic marks have been reported
to escape reprogramming’s broad epigenetic erasure. While
attempting to differentiate iPS cell lines derived from different
tissues into various lineages, our laboratory noted that the re-
programmed cells tended to differentiate preferentially into the
lineage from which they were originally derived, and in some
cases, they retain residual methylation reflective of the donor
cell. These data argue that iPS cells have an epigenetic memory
in which a small number of epigenetic marks fail to be reset
during reprogramming, apparently at random (Kim et al., 2010,
2011). Another recent paper identified randomly located methyl-
ation differences between iPS and ES cells. The authors noted
that the methylation profiles of the iPS lines became more and
more like those of the ES cells upon continued passage (Nishino
et al., 2011). Other studies have found that certain chromosomal
regions near telomeres and centromeres may be particularly
resistant to epigenetic erasure during reprogramming and that
DNAmethylation differences in these regionsmay bemaintained
even during differentiation (Lister et al., 2011).
Studies on Prader-Willi and Angelman syndromes have also
described the fate of imprinted genes during reprogramming
(Chamberlain et al., 2010; Yang et al., 2010). To the surprise of
the authors, these disease-associated gene imprints were unal-
tered during iPS cell generation. These results suggest that,
although the majority of developmentally accrued methylation
marks are reset during reprogramming, the process does not1114 Cell 148, March 16, 2012 ª2012 Elsevier Inc.revert cellular identity all the way back to a pre-imprinting epige-
netic state.
Sources of Epigenetic Variation In Vivo: Environment
and Stochasticity
Environmental exposures have long been known to introduce
changes into the epigenome. Although most environmental
events are only transient phenomena, they often have a lasting
effect on cellular behavior by causing changes to the epigenome.
Cells modify their transcriptional activity in response to chemical
exposures, nutrition, or physical stress, and such changes can
be an enduring legacy of a significant environmental event (Bell
and Spector, 2011; Waterland and Jirtle, 2004; McGowan
et al., 2009; Anway et al., 2006).
Stochastic processes also introduce variability to epigenetic
organization. The fidelity of inheriting site-specific maintenance
ofmethylation in humans has been estimated at 90%–98% (Ush-
ijima et al., 2003; Genereux et al., 2005). However, even this
modest error rate makes it clear that variation is introduced
into the methylome with every cell division at a much higher
rate than DNA sequence mutations would ever accumulate.
Unlike epigenetic modifications that may occur predictably in
response to environmental events, this type of change in DNA
methylation occurs randomly.
Between environmentally induced and stochastic epigenetic
changes, over time, an individual’s epigenome is slowly altered
to reflect the events of his or her individual experiences (Wong
et al., 2010). Some individuals may also have a genetic predispo-
sition to large or small epigenetic oscillations (Bjornsson et al.,
2008; Feinberg and Irizarry, 2010). Given that some or many of
these changes will effect gene expression, an individual’s epige-
netic signature determines how their cells will react in certain
circumstances, and so can predispose to disease or health.
Genetic, Environmental, and Epigenetic Contributions
to Complex Diseases
Despite possessing identical genomes, it is common for one
monozygotic twin to suffer from a complex disease while the
other is unaffected. Monozygotic twins are often discordant for
multifactorial disorders that strike later in life, such as schizo-
phrenia, type II diabetes, and Parkinson’s disease. Traditionally,
phenotypic variability has been viewed as the sum of genetic
variability and environmental variability (Visscher et al., 2008),
such that all differences between monozygotic twins are due
to the shared genotype’s reactions to different environments.
However, this view commingles the effects of immediate envi-
ronmental exposures and lasting epigenetic changes, and it
also ignores epigenetic alterations caused either by stochastic
processes or by genetic predisposition to variability. Failure to
distinguish between causal environmental exposures and causal
epigenetic changes may impair our ability to identify and analyze
appropriate phenotypes of in vitro models of disease. Thus,
when considering disease etiology for modeling, it may be
more informative to view cellular disease phenotypes as having
three classes of contributing factors, each of which is trans-
mitted differently.
Genetic Predisposition. Variations in DNA sequence can
increase or decrease the likelihood of a cellular phenotype.
DNA sequences are transmitted fully and accurately during cell
division.
Environmental Exposures (Nonepigenetic). Immediate envi-
ronmental conditions impact cell health and behavior, such as
nutritional deficiency, hyperglycemia, or chemical exposure.
These conditions are external and not transmittable to daughter
cells.
Epigenetic Effects. These stable and highly transmissible
changes in gene expression are caused by (1) environmental
events, (2) stochastic epigenetic changes, and (3) genetic
predisposition to variability.
With this in mind, human illness can be viewed as the sum of
the genetic, environmental, and epigenetic factors (Petronis,
2006). Attempts to model diseases by iPS cell-derived
approaches should take all of these into account. A few rare
disorders are caused by a single one of these effects, but
many common diseases have the full triad of causes. Here, we
first examine examples of these rare, single-factor disorders,
and then we discuss the more common phenomenon of multi-
factorial disease.
Genetic Diseases
Monogenic disorders are those diseases in which a single gene
is responsible for the presence, absence, or severity of a partic-
ular phenotype. The gene variants that are responsible for these
types of disorders include the CAG repeats of Huntington’s
disease, the mutant clotting factors in hemophilia, and the
altered ion channels in congenital long QT syndrome. There
also may be multigenic conditions in which the combination of
specific gene variants causes disease regardless of environ-
mental or epigenetic effects or in which somaticmutation causes
the disease. For disorders in which the DNA sequence is respon-
sible for the disease, iPS cells generated from cells with this
sequence will bear the causal genotype. Whether or not the
responsible locus or loci have been identified, when patient-
specific iPS cells are differentiated into relevant cell types, the
same genetic defect that caused the patient’s disorder will be
present in the differentiated cells.
Environmental Diseases
Environmental exposure disorders are those in which an environ-
mental condition directly causes the ailment. In the case of a skin
burn caused by exposure to boiling water, 100%of the observed
burn phenotype is attributable to the environmental exposure.
There is no epigenetic or genetic cause, and the heritability is
zero. Comparing iPS cells generated from a patient who has sus-
tained a burn to iPS cells from someone who has not been
burned is unlikely to yield information relevant to burn patho-
physiology.
Epigenetic Diseases
Epigenetic disorders are those in which the phenotype is caused
by an epigenetic state of the genome. Thismay be entirely due to
the aberrant expression pattern of a single gene, as in rare
syndromes like fragile X or Prader-Willi, or the much more
common global misregulation in which innumerable environ-
mentally induced and stochastic epigenetic events affect overall
disease predisposition (Feinberg et al., 2010). Although the
single genes responsible for fragile X or Prader-Willi are individ-
ually regulated during development and thus appear to be resis-
tant to epigenetic change during reprogramming, the countlesssmall epigenetic modifications that predispose an individual to
complex disease are more likely to be erased during the reprog-
ramming process. As noted above, epigenetic variation can arise
in response to environmental exposures stochastically and even
in response to specific genotypes. Regardless of the source of
the epigenetic change, in a few rare conditions, 100% of the
observed phenotype is due to epigenetic variation. Phenotypes
caused by epigenetic changes include phenomena such as
neural tube malformations after global DNA hypomethylation. It
has not yet been investigated whether the flawed epigenomes
underlying disorders like this one will remain after iPS cell gener-
ation. However, given the widespread reprogramming of the
epigenetic status of the cells, such perpetuation seems unlikely.
If a disease does not fall cleanly into one of the three cate-
gories above, then the phenotypic variation is a sum of the triad
of genetic, epigenetic, and environmental variations. An example
of such a condition is sunburn after exposure to the sun’s ultra-
violet radiation. In this case, the geneticmakeup of the individual,
as it relates to skin pigmentation, contributes to resistance or
predisposition to burning upon exposure to sunlight. In addition,
recent ultraviolet exposure that induces genes that produce the
photoprotectant melanin may also contribute to burn protection.
And finally, intensity and duration of exposure to the damaging
radiation will affect the severity of the resulting burn. A reprog-
ramming-based model of sunburn would need to take all three
of these factors into account to reproduce a physiologically
accurate in vitro model of sunburn.
An interesting subset of complex disorders has both familial
and sporadic inheritance patterns but drastically different herita-
bility values. For example, the familial PD variant caused by the
a-synuclein A53T mutation has a heritability of nearly 100%,
whereas the diagnosis of idiopathic PD is estimated to show
lower heritability of only 30%–40% (Golbe et al., 1990; Hamza
and Payami, 2010; Do et al., 2011). Although familial versions
of common complex diseases often have distinctive features
such as age of onset and severity of symptoms, the underlying
cellular pathology often appears consistent between familial
and idiopathic versions of disease (e.g., the loss of dopaminergic
neurons from the substantia nigra in PD).
Value of Stem Cell-Based Disease Modeling
Patient-Specific Disease Modeling Will Be Most Useful
for Diseases with Large Genetic Components
During reprogramming of somatic cells to pluripotency, epige-
netic histories are erased, and standard tissue culture conditions
normalize all environmental differences. Of the genetic, environ-
mental, and epigenetic variations that lead to complex disease,
the only source of variation likely to be faithfully maintained in
iPS cell lines is the genetic variation (Figure 3).
Table 1 lists publications to date in which iPS cells were
derived from patients and subsequently differentiated into the
target cells affected by the relevant disorder. Some of these
papers observed significant differences between the patient-
specific lines and control, whereas others did not. Only one
paper has identified a cellular disease phenotype associated
with a multifactorial disorder, which was schizophrenia. Schizo-
phrenia is one of the most highly heritable complex disorders,
with heritability estimates upwards of 80% (Cardno et al.,Cell 148, March 16, 2012 ª2012 Elsevier Inc. 1115
Figure 3. Utility of Patient-Specific and Induced Disease iPS Cell-Based Disease Models
Healthy control cells can be cultured, reprogrammed to iPS cells, and then differentiated into a target cell type as a control for disease phenotype assays. Cells
from patients with monogenic or highly penetrant genetic disease predisposition can be cultured, reprogrammed, and differentiated to the cell type responsible
for the disorder. Because the genetic predisposition to disease is present in the final cell, this cell is likely to show disease-specific phenotypes when compared to
the healthy control. For diseases caused by environmental and/or epigenetic events, some cell types may not have experienced the causative events. Cells
without environmental or epigenetic predisposition to disease can be cultured, reprogrammed, and differentiated, but because they never carried a predispo-
sition to disease, the resulting cells are unlikely to demonstrate a disease-specific phenotype. Cells affected by a disease-causing environmental or epigenetic
event can be cultured, in which environmental conditions are standardized, and reprogrammed, in which the epigenome is reset. After these factors are
normalized, these cells no longer carry a predisposition to disease. Thus, the iPS lines and differentiated cells resulting from this approach are unlikely to
demonstrate disease-specific phenotypes.
Cells from any source can be exposed to disease-inducing environmental conditions to create a model of an environmentally induced disorder. This could be
during reprogramming (as shown), during differentiation, or during extended culture. Cells from any source can be epigenetically manipulated tomimic epigenetic
alterations contributing to disease. Pink, healthy; green, predisposed to disease.1999). All other publications that have shown disease-associ-
ated cellular phenotypes have been investigating genetic disor-
ders (Table 1).
We predict that the value of patient-specific iPS cell-based
disease modeling will be directly proportional to the disease
heritability. What then are the prospects for modeling multifacto-
rial diseases with genetic, environmental, and epigenetic
components? The field is placing a bet that cells derived from
patients who carry a highly penetrant genetic disease predispo-
sition will provide insight into pathologic mechanisms of both the
monogenic and multifactorial versions of the disorder.
Is this hope sound? It will be for sporadic forms of disease that
have as their molecular underpinnings spontaneously arising
mutations in genes that function in the same tissues as the
familial forms. These are typically somatic mutations. Conse-1116 Cell 148, March 16, 2012 ª2012 Elsevier Inc.quently, they are expected to show similar cellular pathologies
in vitro—if the iPS cells happen to capture the somatically
acquired disease-causing mutation. In other cases, a patient
with sporadic disease may have a genotype that only predis-
poses to the disease, perhaps in the setting of specific environ-
mental insults, and thus shows incomplete penetrance. In these
cases of complex diseases that show significant heritability but
no Mendelian inheritance pattern, the genetic disease predispo-
sition will be present in the stem cell and the resulting model.
Finally, it is also possible that, in some cases, the combined envi-
ronmental and epigenetic influences on the target tissue in an
affected patient produce a cellular pathology that mimics that
of the genetic version of the disease but that carries no overt
or detectable genetic contributor. In this case, reprogramming
will erase all vestiges of the environmental insults that caused
Table 1. Patient-Specific iPS Lines that Have Been Differentiated into a Disease-Relevant Cell Type
Cellular Disease Phenotype Identified
Type Disorder Publication
Genetic a1-antitrypsin deficiency (Rashid et al., 2010)
Genetic Adrenoleukodystrophy, X-linked (Jang et al., 2011)
Genetic Alzheimer’s disease, familial (Yagi et al., 2011)
Genetic Amyotrophic lateral sclerosis, familial (Mitne-Neto et al., 2011)
Genetic Atypical Werner syndrome (Cy Ho et al., 2011)
Genetic Chronic granulomatous disease, X-linked (Zou et al., 2011b)
Genetic Down syndrome (Baek et al., 2009)
Genetic Duchenne muscular dystrophy (Kazuki et al., 2010)
Genetic Dyskeratosis congenita (Agarwal et al., 2010)
Genetic Epidermolysis bullosa (Tolar et al., 2011b)
Genetic Familial dysautonomia (Lee et al., 2009)
Genetic Fragile X syndrome (Urbach et al., 2010)
Genetic Gaucher’s disease (Mazzulli et al., 2011)
Genetic Glycogen storage disease type 1A (Rashid et al., 2010)
Genetic Huntington’s disease (Zhang et al., 2010)
Genetic Hurler syndrome (Tolar et al., 2011a)
Genetic Hutchinson-Gilford progeria (Liu et al., 2011)
Genetic Hypercholesterolemia, familial (Rashid et al., 2010)
Genetic Inherited dilated cardiomyopathy (Cy Ho et al., 2011)
Genetic LEOPARD syndrome (Carvajal-Vergara et al., 2010)
Genetic Long QT syndrome (Moretti et al., 2010; Itzhaki et al., 2011; Lahti et al., 2011)
Genetic MPS type IIIB (Lemonnier et al., 2011)
Genetic Myeloproliferative disorder (Ye et al., 2009)
Genetic Parkinson’s disease, familial (Seibler et al., 2011; Nguyen et al., 2011; Devine et al., 2011)
Genetic Retinitis pigmentosa (Jin et al., 2011)
Genetic Rett Syndrome (Marchetto et al., 2010)
Genetic Sickle cell disease (Zou et al., 2011a)
Genetic Spinal muscular atrophy (Ebert et al., 2009)
Genetic Timothy syndrome (Ebert et al., 2009)
Genetic Wilson’s disease (Zhang et al., 2011b)
Multifactorial Schizophrenia (Brennand et al., 2011)
No Cellular Disease Phenotype Determined
Type Disorder Publication
Genetic ADA-severe combined immunodeficiency (Park et al., 2008a)
Genetic Becker muscular dystrophy (Park et al., 2008a)
Genetic Crigler-Najjar syndrome (Ghodsizadeh et al., 2010)
Genetic Cystic fibrosis (Somers et al., 2010)
Genetic Gyrate atrophy (Howden et al., 2011)
Genetic Osteogenesis imperfecta (Khan et al., 2010)
Genetic Progressive cholestasis, familial (Ghodsizadeh et al., 2010)
Genetic Shwachman-Bodian-Diamond syndrome (Park et al., 2008a)
Genetic Tyrosinemia type 1 (Ghodsizadeh et al., 2010)
Multifactorial Diabetes type 1 (Maehr et al., 2009)
Multifactorial Parkinson’s disease, sporadic (Soldner et al., 2009; Hargus et al., 2010; Swistowski et al., 2010)
Multifactorial Scleroderma (Somers et al., 2010)
Most lines to date that have been differentiated into disease-relevant cell types have been from patients with genetic disease. Identifying a disease-
specific phenotype in differentiated cells from patients with multifactorial disease has been less successful than from patients with genetic disease.
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Figure 4. iPS Cell-Based Triad Model of Complex Disease
In an experimental system with a reliable cellular disease phenotype readout,
constancy of any two variables allows investigation of the other’s effect on the
disease phenotype.the disease, and comparisons of highly heritable familial forms of
disease to sporadic cases will prove unrevealing. It is likely that
future research will validate each of the above scenarios.
Stem Cell-Based Models for Diseases with Significant
Environmental or Epigenetic Components Require
Experimental Induction of the Disease
Despite the erasure of environmental and epigenetic causes of
disease by reprogramming, pluripotent stem cell-based models
may still prove useful for nongenetic diseases.When the environ-
mental or epigenetic factors responsible for causing disease are
well understood, it may be possible to induce them experimen-
tally in culture, even if interactions among distinct cell types
are required. For example, by differentiating iPS cells into kera-
tinocytes and melanocytes, which communicate in response to
exposure to ultraviolet light (Lin and Fisher, 2007) and could be
organized into a facsimile of an epidermis in vitro, the phenom-
enon of sunburn could be investigated by this experimental plat-
form, as the genetic, epigenetic, and environmental causes are
relatively well understood. This leads to a well-controlled triad
experimental model, in which as long as two of the three vari-
ables are held constant, the third can be manipulated to test
hypotheses: (1) iPS cell-derived epidermis could be generated
from individuals with inherited sunburn predisposition to learn
about the genetic factors affecting the process; (2) various inten-
sities and durations of ultraviolet light could be applied to the
epidermis in culture to investigate cellular responses to different
severities of environmental exposure; (3) epidermis in culture
could be subjected to repeated ultraviolet exposures to induce
gene expression leading to melanin formation, allowing for study
of the mechanisms by which the environmental exposure leads
to the change in gene expression. This triad model (Figure 4)
would provide a much-needed tool to investigate directly the
effects of epigenetic manipulations on cellular disease states.
It would also be useful for teasing apart genotype by environ-
ment or genotype by epigenetic disease effects because the
behavior of cells with various genetic backgrounds could be
directly compared.
Using this technique to approach diseases of poorly under-
stood etiologies requires a leap of faith that researchers will be
able to induce, identify, and exploit a credible cellular pathology.
Given that many disorders are late onset, researchers might first
discern how to accelerate disease latency from many decades1118 Cell 148, March 16, 2012 ª2012 Elsevier Inc.in actual patients to no more than weeks to months in vitro.
Moreover, they may be required to re-create the environmental
and epigenetic changes induce the cellular phenotype respon-
sible for the disease. A triad model for poorly understood disor-
ders is an admirable goal that will require much work before it
bears fruit.
Future Benefits
In addition to the disease models and drug screens currently
being developed, the wholesale conversion of one cell type to
another has compelled scientists to entertain new phenomena
in cellular and developmental biology, and it has inspired
clinicians to conceive new therapeutic opportunities. Myriad
diseases are caused by the lack of a crucial cell or an indispens-
able protein; the ability to cure disease by replacing the missing
component is the promise of stem cell engineering and regener-
ative medicine.
Two broad approaches could be taken to restore a missing
cell type: (1) creation of iPS cells followed by directed differenti-
ation into the missing cell type, which would then be incorpo-
rated into the patient in an anatomically appropriate fashion, or
(2) direct conversion of an extant healthy cell type into the
missing or damaged cell type, thus effecting cell regeneration
in situ.
The first of these possibilities has many elements in common
with the approaches currently being taken to create disease
models, requiring GMP reprogramming procedures and precise
directed differentiation protocols that eliminate the possibility of
stem cell-derived tumors. Diseases of different systems each
need an approach for attaining lasting integration of the new
cells. This will vary by organ and may be straightforward for
some disorders, such as those requiring hematopoietic stem
cells, but much more difficult for others, such as neurodegener-
ative conditions requiring specific neuronal connections to be
made.
The second approach to cell therapy would be to manipulate
cellular identity in situ to generate the missing cell type in an
appropriate anatomical location. A groundbreaking study from
the Melton group investigated in vivo conversion of cell types
inside the pancreas (Zhou et al., 2008). They found that infection
of pancreatic exocrine cells with viruses expressing develop-
mental pancreatic genes resulted in the in situ formation of cells
that looked and behaved like b cells, including an ability to rectify
hyperglycemia. Unlike the iPS cell-based approach to cellular
therapy, this direct conversion method has no risk of residual
pluripotent cells. Instead, the main hurdles are the targeted
delivery of the conversion agents to the appropriate areas and
the prevention of partially converted or transformed cells. As
with tissue metaplasia in the setting of tissue pathology, manip-
ulation of cellular identity in vivomight carry the worrisome risk of
neoplasia.
In addition to the experimental and possibly therapeutic tools
generated by manipulating cellular identity in vitro, these tech-
niques may provide new ways to study diseases of aberrant
cell fates, such as metaplasia, neoplasm, and developmental
disorders. It has not escaped anyone’s notice that the original
Yamanaka reprogramming factors—Oct4, Sox2, KLF4, and
Myc—are in distinct contexts potent transforming oncogenes.
Indeed, reprogramming mimics the dedifferentiation surmised
for some tumors, and insights into the mechanisms of reprog-
ramming are bound to yield new discoveries of mechanisms of
oncogenic transformation. Because specific fate changes can
now be induced in mammalian cells, researchers have the
opportunity to interrogate the mechanisms by which a cell is
coerced to change its identity, whether in the natural course of
tissue differentiation, the distinctly pathologic course of dediffer-
entiation, the engineered fates of transdifferentiation, or themost
dramatic of fate changes—reprogramming to pluripotency.
Conclusions
The discovery of cellular reprogramming and the realization that
cellular identity is malleable and subject to engineering has
compelled researchers to think in bold ways about new
approaches to research disease mechanisms, drug develop-
ment, and cell-based treatments for a range of diseases.
However, recognizing that many diseases have significant envi-
ronmental and epigenetic contributions, we anticipate that, in the
near term, patient-specific stem cell-based disease models will
be most useful for those disorders with highly penetrant genetic
etiologies. In addition, we predict that this first wave of models
will teach important lessons about precisely what aspects of
pathophysiology can and cannot be gleaned from a disease-
in-a-dish, including the impact of epigenetic memory and imper-
fect reprogramming on disease models. Using pluripotent stem
cells to model diseases with only small genetic contributions
may prove feasible but will present more formidable challenges.
It will also depend on recapitulating environmental and epige-
netic influences so that the relevant genetic and nongenetic
factors collude to faithfully reproduce disease phenotypes
in vitro. Given the pace of current research and the rapid accu-
mulation of publications describing iPS cell-based disease
models, the advantages and limitations of this new research
platform are bound to come into focus, yielding principles that
will guide future research within realistic expectations.
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